Thousands of healthcare professionals have gathered in Barcelona for one of the highlights of the annual global rheumatology conference calendar.
The European Congress of Rheumatology (EULAR 2025) has kicked off in Barcelona, uniting more than 18,000 healthcare professionals, researchers and patient advocates from more than 130 countries.
This year’s congress, held from June 11 to June 14, marks a significant milestone in the global effort to advance the understanding and treatment of rheumatic and musculoskeletal diseases.
Under the leadership of Congress Chair Professor Christian Dejaco and Abstract Chair Professor Bimba Hoyer, the program delves into both common and rare RMDs, featuring state-of-the-art lectures, abstract sessions and hands-on practical skills workshops.
A highlight of the opening plenary ceremony included a session on Still’s Disease in Children and Adults, followed by the official opening of the exhibition and scientific sessions.
Patient engagement is a strong focus of the conference, with sessions such as “From Exclusion to Empowerment: Engaging Marginalised Groups” and “How Do Drug Prices Influence Treatment Decisions?” fostering dialogue between clinicians, researchers and patients.
Four leading Australian rheumatologists and researchers will be among the presenters, including Rheumatology Republic’s deputy editor Dr David Liew, who has a poster presentation on a consumer-driven approach to Australian arthritis research, and a presentation and Q&A on JAKs and infections, and whether they’re better or worse than biologics.
Related
Professor David Hunter will participate in a debate on platelet enriched plasma (PRP) for the treatment of OA.
Dr Kate Seaton has a poster presentation quantifying the prevalence of gut-brain interaction in systemic sclerosis.
Professor Ranjeny Thomas will present at a session on dendritic cells and tolerizing immunotherapy, and will also participate in a Q&A on the subject.
New Zealand’s Professor Lisa Stamp has a poster presentation on colchicine concentrations and relationship with colchicine efficacy and adverse events; post-hoc analysis of a randomised clinical trial of colchicine for gout flare prophylaxis.
Fellow New Zealander Professor Simon Stebbings will make an oral abstract presentation on bowel symptoms that are common and persistent in axial spondylarthritis, impact quality of life and correlate with both higher faecal calprotectin and disease activity scores.
The congress continues until Saturday 14 June. For more information and to access the full program, visit the official EULAR 2025 website here.
